This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

计划入组 5 人 · 首次发布于 2025 年 8 月 3 日

The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease

计划入组 6 人 · 首次发布于 2024 年 9 月 23 日

The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

计划入组 40 人 · 首次发布于 2023 年 12 月 12 日

Human dopaminergic precursor (Wuhan Ruijian)

glial progenitor cell therapy

immunoregulatory progenitor cell therapy

METABOLIC THERAPY, INC.

United States

Everads Therapy Ltd.

Israel

ATI Physical Therapy

United States

BrainXell's BXT-110 Shows Promising Preclinical Results for Parkinson's Disease Cell Therapy

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program with FDA Fast Track Status

iRegene's NouvNeu001 Becomes First iPSC Therapy to Receive Both FDA Fast Track and RMAT Designations for Parkinson's Disease